The Clinic
Daraxonrasib’s FDA Nod: A Rare Win for Pancreatic Cancer, Priced for Investors
On 26 August the FDA approved Rasonque (daraxonrasib), a RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma after prior therapy. The science is first-in-class. The invoice is not a public good.